Omeros Stock Price

0.00 (0.0%)


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Omeros Corporation OMER NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 18.41 07:00:49
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
17.41 18.65 1.24 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 18.41 USD

Omeros Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.14B 61.65M 58.94M $ 111.80M $ - -1.71 -8.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Omeros News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OMER Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week17.6318.4916.7117.50579,1020.784.42%
1 Month18.9320.4816.7118.26546,595-0.52-2.75%
3 Months18.3023.8516.3819.79688,6600.110.6%
6 Months11.3923.859.9816.41762,2557.0261.63%
1 Year13.9725.499.2515.17873,0824.4431.78%
3 Years14.2627.008.5015.91723,2694.1529.1%
5 Years14.9727.08827.2015.67731,3543.4422.98%

Omeros Description

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.